-
In this issue: Depression and pregnancy, new vaccine recommendations from the CDC, cortico-steroids and/or antivirals for Bell's palsy, rasagiline and Parkinson's disease, and FDA Actions.
-
It has been known for years that patients with chronic fatigue syndrome (CFS) have a defect in a major antiviral pathway, the 2-5A/RNase L pathway. The RNaseL produces non-specific viral cleavage and, thus, protects us from many viral infections (innate immunity).
-
-
Data showing an increased risk of MRSA and C. difficile colonization on the footpads and coats of dogs and cats used for pet therapy in hospitals was discussed briefly in May 2009.
-
-
n this issue: WHO recommendations for antiviral use for H1N1 flu; antibiotic use trends for acute respiratory tract infection; denosumab clears FDA Expert Panel; FDA Actions.
-
The 2009 update of hiv primary care guidelines make several new recommendations, and the evidence basis for these is documented in the paper.
-
A randomized, double-blind, placebo-controlled, multicenter study was conducted from 2002-2006 at 25 institutions in France of the effect of prophylactic recombinant granulocyte-colony stimulating factor (rG-CSF) on nosocomial infections and survival among preterm neonates with persistent neutropenia.
-
Typhoid fever sickens more than 16 million people worldwide and causes up to 600,000 deaths annually, mostly in developing countries.
-
Artemisinins are the most rapidly acting antimalarials available, have few serious side effects, and have been used extensively with few reports of resistance until recently.